Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral T-cell lymphomas.

Kerry J Savage1

  • 1British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada. ksavage@bccancer.bc.ca

Blood Reviews
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Peripheral T-cell lymphomas (PTCLs) are rare, diverse cancers with poor prognoses. Further research and targeted clinical trials are crucial for understanding and improving PTCL treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Haematologica·2026
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Area of Science:

  • Oncology
  • Hematology

Background:

  • Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of lymphoid malignancies.
  • PTCLs are significantly less understood than B-cell lymphomas, with poorly defined optimal treatment strategies.

Purpose of the Study:

  • To highlight the biological diversity and rarity of PTCLs.
  • To underscore the poor prognosis associated with most PTCL subtypes.
  • To emphasize the need for further research and tailored therapies for PTCL.

Main Methods:

  • Review of existing literature on PTCL.
  • Analysis of prognostic factors, including the International Prognostic Index (IPI).
  • Exploration of subgrouping strategies based on T-helper chemokine receptor profiles and gene expression profiling.

Related Experiment Videos

Main Results:

  • Most PTCL subtypes, excluding ALK-positive anaplastic large cell lymphoma (ALCL), have a dismal 5-year overall survival rate of 15-30%.
  • The IPI is a useful tool for risk stratification in certain PTCL subtypes like PTCL unspecified (PTCLU).
  • Subgrouping PTCLU based on molecular profiles shows potential for guiding future therapeutic approaches.

Conclusions:

  • PTCLs require dedicated research efforts due to their complexity and poor outcomes.
  • Developing targeted therapies based on molecular characteristics is essential for improving patient survival.
  • Future clinical trials focused on PTCL are imperative for advancing management strategies.